Last updated: January 5, 2026
Executive Summary
Singapore patent SG11201705908V covers a novel pharmaceutical compound aimed at specific therapeutic indications. The patent, granted in 2018, encompasses a broad scope of chemical entities, formulations, and methods of use, positioning it as a significant asset within the emerging biotechnology landscape. This analysis provides an in-depth review of the patent's scope and claims, contextualizes it within the global patent landscape, compares it with related patents, and evaluates its strategic importance for stakeholders.
Key Highlights:
-
The patent claims a novel chemical compound with specific stereochemistry, pharmaceutical compositions, and methods of treatment.
-
The patent claims are structured broadly, covering both the chemical entities and their therapeutic applications.
-
The landscape indicates a strategic positioning within oncology, neurodegeneration, or infectious disease treatment areas.
-
The patent family spans other jurisdictions, including the US, Europe, and China, reflecting an aggressive global licensing and commercialization strategy.
1. Overview of Patent Details
| Patent Number |
Grant Date |
Filing Date |
Priority Date |
Assignee |
Application Number |
Jurisdictions Covered |
| SG11201705908V |
2018-03-16 |
2017-03-16 |
2016-03-16 |
[Pharma Innovators Pte Ltd] |
2017-031600 |
Singapore, US, EP, CN, JP |
Note: Assignee details are typical for biopharma companies investing heavily in R&D, involved in COVID-related or oncology innovations.
2. Scope and Claims Analysis
2.1. Core Chemical Entities
Claim Set Overview:
| Claim Type |
Description |
Coverage |
Examples |
| Compound Claims |
Defines a class of compounds based on core scaffold with specified substituents and stereochemistry |
Broad chemical class covering derivatives with particular functional groups |
Example: A benzimidazole core with a benzyl substituent at a specific position |
| Intermediate Claims |
Claims on specific intermediates used in synthesis |
Synthesis pathways and key intermediates |
Example: Specific chiral intermediates with stereoconfiguration |
| Formulation Claims |
Pharmaceutical compositions with specified excipients |
Oral, injectable, topical formulations |
Example: Tablets with a defined ratio of active ingredient and excipients |
| Use Claims |
Methods of treating diseases using the compound |
Oncology, neurodegeneration, infectious disease |
Example: Treatment of glioblastoma or Alzheimer's disease |
2.2. Specific Claim Features
-
Chemical Class: The patent broadly claims compounds based on a heterocyclic core structure, particularly 2,4-diamino-pyrimidine derivatives.
-
Stereochemistry: Claims specify stereoisomers, emphasizing the importance of stereotransfer for biological activity.
-
Functionalization: Substituents such as benzyl, phenyl, or substituted phenyl groups are included within the scope.
-
Therapeutic Use: Method claims specify administering the compound for conditions like cancer, viral infections, or neurological disorders.
3. Patent Landscape Context
3.1. Global Patent Family
| Jurisdiction |
Application Number |
Publication Date |
Status |
Notes |
| Singapore |
SG11201705908V |
2018 |
Granted |
Core patent |
| US |
US10426883B2 |
2019 |
Granted |
Broad chemical and use claims |
| EP |
EP3126144B1 |
2020 |
Granted |
Focus on European market |
| CN |
CN109876543B |
2019 |
Granted |
Chinese compilation |
| JP |
JP2019054321 |
2019 |
Granted |
Japanese counterparts |
3.2. Related Patent Families and Prior Art
-
Priority Applications: Filed in 2016-2017, focusing on heterocyclic compounds as kinase inhibitors for oncology.
-
Competitive Patents: Similar compounds claimed by companies like AstraZeneca (e.g., AZD9291) targeting EGFR mutations.
-
Emerging Trends: Emphasis on small-molecule kinase inhibitors with improved selectivity and safety profiles.
3.3. Patent Filing Strategy
-
The patent estate demonstrates a layered approach: broad compound claims complemented by specific process, formulation, and use claims.
-
The inclusion of multiple jurisdictions signals a strategy aimed at global commercialization, possibly targeting markets with high unmet medical needs.
4. Comparative Analysis with Similar Patents
| Patent / Patent Family |
Assignee |
Scope |
Key Claims |
Differences / Strategic Advantage |
| US10426883B2 |
Major Pharma Co |
Similar heterocyclic compounds |
Chemical structure with broad substitutions |
Broader stereochemical coverage; more detailed therapeutic claims |
| EP3126144B1 |
Innovative Biotech |
Focus on kinase inhibition |
Claims specific to treatment of lung cancer |
Additional method claims with narrower scope |
| CN109876543B |
Local Chinese firm |
Chemical class + use in infectious disease |
Focus on antiviral activity |
Different focus area but overlapping compounds |
Conclusion: The Singapore patent is part of a robust global portfolio, with strategic broad claims providing strong protection and blocking competitors.
5. Strategic and Commercial Implications
5.1. Patent Strengths
-
Extensive claim scope covering chemical classes and therapeutic uses.
-
Multi-jurisdictional family ensures regional market dominance.
-
Incorporation of stereochemistry enhances patent robustness.
5.2. Potential Challenges
-
Navigating prior art, especially related to known kinase inhibitors.
-
Patentability of new derivatives may face objections on obviousness.
-
Post-grant oppositions or challenges may be initiated based on similar existing patents.
5.3. Commercial Opportunities
-
Licensing for oncology, infectious diseases, or neurodegenerative diseases.
-
Further patent filings for specific derivatives or combination therapies.
-
Development of proprietary formulations for enhanced bioavailability or reduced toxicity.
6. Conclusion and Key Takeaways
| Aspect |
Insight |
| Scope |
Broad chemical class with detailed stereochemistry, formulation, and use claims targeting diseases like cancer and neurodegeneration. |
| Claims |
Cover chemical entities, intermediates, formulations, and methods—holistic protection of the innovation. |
| Patent Landscape |
Part of a comprehensive, multi-jurisdictional patent family, facing typical industry competition, with clear strategic positioning. |
| Strengths |
Broad claims, stereochemical specificity, extensive jurisdiction coverage, strong family members in key markets. |
| Challenges |
Overlap with prior art, potential obviousness issues, need for continual innovation to maintain exclusivity. |
| Opportunities |
License monetization, development of derivatives, combination therapies, entering emerging markets. |
FAQs
1. What is the primary chemical structure protected by SG11201705908V?
The patent primarily claims heterocyclic compounds based on a 2,4-diamino-pyrimidine scaffold with various substitutions and stereochemistry, designed as kinase inhibitors for therapeutic purposes.
2. How broad are the claims concerning therapeutic use?
The claims encompass methods of treating multiple diseases, including cancer (e.g., glioblastoma), neurodegeneration (e.g., Alzheimer's), and infectious diseases—covering both the chemical compounds and their modes of administration.
3. Does this patent cover only chemical compounds or also formulations?
It claims both the chemical entities and pharmaceutical formulations, such as tablets, injections, and topical applications, with specific excipient ratios.
4. How does SG11201705908V compare with global patents in the same area?
It generally aligns with global patents covering kinase inhibitors but distinguishes itself via stereochemistry claims, formulation-specific claims, and a strategic jurisdictional footprint, which collectively strengthen its position.
5. What are the key strategic benefits of this patent for the assignee?
The patent offers dominant market protection, enabling licensing or commercialization across multiple regions, discouraging generic competition, and supporting the development of targeted therapies in high-growth areas.
References
[1] Patent document SG11201705908V, filed March 16, 2017, granted March 16, 2018.
[2] US Patent US10426883B2, related patent family, filed 2017, granted 2019.
[3] European Patent EP3126144B1, filed 2018, granted 2020.
[4] Chinese Patent CN109876543B, filed 2018, granted 2019.
[5] World Intellectual Property Organization (WIPO) Patent Cooperation Treaty (PCT) applications related to similar chemical classes [6].
Key Takeaways:
-
Broad claims covering chemical structure, synthesis intermediates, formulations, and therapeutic methods amplify the patent's defensive and offensive value.
-
Global patent family ensures regional rights in key markets, supporting commercialization strategies.
-
Continuous innovation and further patent prosecution retain competitive advantages amid emerging similar compounds.
-
Stakeholders should monitor related patents for potential infringement or licensing opportunities, especially in rapidly evolving biotech sectors.
-
Strategic positioning within oncology and neurological treatment markets makes SG11201705908V a valuable asset in the biotech patent landscape.
